Safety Study to Evaluate FluMist in Immunocompromised Children

Study identifier:MI-CP114

ClinicalTrials.gov identifier:NCT00112112

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I Randomized, Double-Blind Trial of the Safety and Immunogenicity of FluMist® A Live, Intranasal Influenza Virus Vaccine vs. Placebo in Immunocompromised Children Ages 5 Through 17 Years of Age

Medical condition

cancer

Phase

Phase 1

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

20

Study type

Interventional

Age

5 Years - 17 Years

Date

Study Start Date: 01 Aug 2005
Primary Completion Date: 01 Mar 2008
Study Completion Date: 01 May 2008

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Prevention

Verification:

Verified 01 Jun 2017 by MedImmune, LLC

Sponsors

MedImmune, LLC

Collaborators

-

Inclusion and exclusion criteria